Perspectives
Optimal Treatment for Patients with Heart Failure with Preserved Ejection Fraction
Abstract
In light of recent studies, how can providers approach and offer optimal care to patients with heart failure with preserved ejection fraction (HFpEF)? As evidenced by years of research, there is clear guidance to treat patients with heart failure with reduced ejection fraction (HFrEF). The data model the benefits of treatment to reduce hospitalizations, improve symptoms, and reduce morbidity and mortality. Data in patients with HFpEF have remained limited, however. Although there has not been statistically significant clinical evidence to support morbidity and mortality benefit in patients with HFpEF, newer evidence with certain pharmacologic therapies show benefit in reducing hospitalizations in HFpEF patients.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777–781.
2. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;3370:1383–1392.
3. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med 2021; 385:1451–1461.
